Perspectives on Life Sciences
307 total results. Page 1 of 13.
AgTech Industry Group Co-Leaders Karen Carr and Alexander Spiegler will speak at the International Bar Association’s 9th Annual IBA World Life Sciences Conference.
For decades, the Securities and Exchange Commission (SEC) and criminal prosecutors have pursued claims for insider trading in securities by persons who learn material nonpublic information about clinical drug trials.
Partner Andy Sawula and Associate Sam Rasche discuss how to respond to EPA Information Requests.
ArentFox Schiff advised Kindeva Drug Delivery in its combination with Meridian Medical Technologies.
ArentFox Schiff represented NorthView Acquisition Corp., a publicly traded special purpose acquisition company, in its merger with Profusa, Inc., a digital health company.
We represented NextPlat Corp., a global e-commerce platform company, in its strategic investments in Progressive Care Inc., a personalized healthcare services and technology company.
ArentFox Schiff advised GBS Inc. (Nasdaq: GBS) on its acquisition of Intelligent Fingerprinting Limited, including its proprietary drugs of abuse screening technology.
Byron Dorgan, Doug Jones*, Philip S. English*, Dan H. Renberg, Jon S. Bouker, Craig Engle, David P. Grosso, Sarah B. “Cissy” Jackson, Oliver Spurgeon III*, Amy Antoniolli, Stephen P. Hanson, Laura E. Doyle, Jeri Freirich*, Daniel Sjostedt*
Americans woke up on Wednesday, November 9, immediately realizing something was different. On their televisions and other devices, they only saw commercials for products, vacation spots, and reality shows.
ArentFox Schiff is pleased to announce that five attorneys have been ranked by LMG Life Sciences, which recognizes the work of outstanding individuals in the life sciences sector.
We represented Boustead Securities, LLC as the sole underwriter in Know Labs, Inc.’s $8.28 million public offering of common stock.
ArentFox Schiff secured an important victory for Azurity Pharmaceuticals, Inc. when the US Court of Appeals for the First Circuit found that the Food, Drug, and Cosmetic Act permits a pharmaceutical company to pursue false advertising claims against a compounding pharmacy, Edge Pharma, LLC.
The Metaverse stands to disrupt nearly every industry – fashion, media and entertainment, real estate, sports, the list goes on – presenting immense possibilities and potential risks. We have created the ArentFox Schiff Industry Guide to the Metaverse to answer questions and anticipate concerns.
ArentFox Schiff is pleased to announce that the firm and two partners have been shortlisted for the annual LMG Life Sciences Americas Awards.
The life sciences and pharmaceutical industry is investigating potential applications in the Metaverse to reduce costs, increase efficiency, and develop novel functionalities.
“Metaverse” is no longer a mere buzzword. Many industries are discovering and developing applications for the Metaverse, and the pharma and biotech industry is no different.
ArentFox Schiff Intellectual Property Partner Alex Spiegler will present at the International Bar Association (IBA) 8th Annual World Life Sciences Conference.
Attorney-Client Privilege Issues: Three Ways Companies Can Shield Privileged Communications From Their Directors
Directors owe fiduciary duties to the company. To make informed decisions and satisfy those fiduciary duties, directors generally have broad access to the company’s books and records, with a few exceptions.
ArentFox Schiff LLP represented The Benchmark Company, LLC as underwriter in Tenon Medical, Inc.’s initial public offering. The $16 million IPO closed on April 29, 2022.
Richard J. Berman, Sailesh K. Patel, Imron T. Aly, Kevin M. Nelson, Bradford C. Frese, Taniel E. Anderson
ArentFox Schiff is sponsoring the ACI Paragraph IV Disputes Conference and Rich Berman and Sal Patel will present.
Back in 2017, the state of Nevada passed a sweeping bill into law that addressed not only drug pricing transparency, but also reporting obligations applicable to pharmacy benefit managers and non-profit organizations and also imposed certain requirements on manufacturer sales forces.
Linda M. Jackson, Alexander H. Spiegler, Lauren C. Schaefer, Allan E. Anderson, Robert K. Carrol, Nicholas J. Nesgos, Alexandra M. Romero, Sara T. Schneider, Natalie C. Kreeger, Pascal Naples, Morgan R. Pankow, Nadia Patel, Jodi Tai
Download Our Summary of the Most Important Cases.
Contract Year 2023 Part D Proposed Rule Released: Changes To 'Negotiated Price' Would Require Potential DIR Fees at the Point of Sale
The Centers for Medicare & Medicaid Services (CMS) published the proposed Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs (the Proposed Rule) on January 12, 2022, in the Federal Register.
The Centers for Medicare & Medicaid Services (CMS) calendar year 2022 rule finalizing changes to payment policies under the Physician Fee Schedule (PFS) and Medicare Part B (the Final Rule) was published on November 19, 2021. The Final Rule takes effect January 1, 2022.
Twenty-five Arent Fox LLP practices have been recognized in the 2022 “Best Law Firms” rankings that are published annually by US News & World Report and Best Lawyers.